New hope for healthcare: Nita Ambani announces 2000-bed Medical City in Mumbai

Mumbai: In a major step to transform the country’s healthcare landscape, Nita Ambani, Founder and Chairperson of Reliance Foundation, announced the establishment of a massive state-of-the-art 2,000-bed medical city in Mumbai.  

The facility will not just be another hospital, but a hub of healthcare innovation where advanced medical technology and artificial intelligence will work alongside some of the world’s finest doctors to provide world-class treatment at affordable costs. This initiative is set to revolutionise the health and medical industry, restructuring and reshaping it with the power of advanced technology to serve humankind better.

Also read- Haryana doctors launch hunger strike against Geo-fencing Attendance System

Sharing the announcement at the 48th Annual General Meeting of Reliance Industries, Mrs. Ambani said, “This will not be just another hospital but India’s new beacon of healthcare innovation, where AI-powered diagnostics, cutting-edge medical technology, and leading doctors from across the globe will come together to deliver care that matches the best standards in the world.”


Beyond patient care, the upcoming medical city will also house a transformative medical college, envisioned to train the next generation of doctors who will serve both India and the world. Nita Ambani emphasised that the mission is not just to expand capacity, but to make world-class healthcare accessible and affordable to every Indian.

The new project builds upon the success of the Sir H. N. Reliance Foundation Hospital, Mumbai’s top multi-speciality hospital, which recently completed a decade of service, serving millions of patients. 

Marking the milestone, Mrs. Ambani also launched “Jeevan” – a state-of-the-art extension of the hospital and the name for the upcoming medical city. The Jeevan wing will focus on pediatric cancer care through chemotherapy and immunotherapy, designed to provide children with advanced treatment in an environment filled with compassion and warmth.

“This wing will be designed to heal our little ones with world-class care and a mother’s warmth,” she explained.

Also read- AIIMS Announces 12-hour a day duty roster: Is it feasible? Here’s what doctors say

Powered by WPeMatico

Sex-selective abortion bans harm maternal and infant health, according to study

Sex-selective abortion bans (SSABs)—which prohibit the seeking of abortions based on the fetus’ sex—increase the likelihood of low birth weight and preterm births among infants born to Asian immigrant mothers, according to a new study by Yale sociologist Emma Zang.

Powered by WPeMatico

Sex-selective abortion bans harm maternal and infant health, according to study

Sex-selective abortion bans (SSABs)—which prohibit the seeking of abortions based on the fetus’ sex—increase the likelihood of low birth weight and preterm births among infants born to Asian immigrant mothers, according to a new study by Yale sociologist Emma Zang.

Powered by WPeMatico

Scientists create realistic brain-wide connection maps through digital modeling

EPFL researchers have developed a powerful method to generate brain-wide, biologically realistic wiring maps of the mouse brain. Their approach bridges experimental data with mathematical and computational modeling to simulate how neurons connect across the entire brain.

Powered by WPeMatico

Scientists create realistic brain-wide connection maps through digital modeling

EPFL researchers have developed a powerful method to generate brain-wide, biologically realistic wiring maps of the mouse brain. Their approach bridges experimental data with mathematical and computational modeling to simulate how neurons connect across the entire brain.

Powered by WPeMatico

Millions of women rely on contraceptives, but a new study shows they may do more than just prevent pregnancy

Hormonal birth control is a fact of life for millions of women. In the U.S. alone, more than 60 million women of reproductive age have used contraceptives according to the Centers for Disease Control and Prevention, most often to prevent pregnancy but also to manage conditions such as endometriosis, polycystic ovary syndrome and irregular cycles.

Powered by WPeMatico

AI models can help predict in-hospital mortality in ICU patients with lymphoma

Machine learning (ML) models predict in-hospital mortality in intensive care unit (ICU) patients with lymphoma, according to a study published online Aug. 20 in PLOS ONE.

Powered by WPeMatico

Scientists solve medical mystery behind rare multi-organ disease, opening door to new treatments

A team of scientists led by Duke-NUS Medical School has solved a mystery behind a rare and previously undiagnosed disease that affects multiple organs, shedding new light on its cause—and offering fresh hope for treatment.

Powered by WPeMatico

Cachexia index as a Biomarker for Cancer Cachexia and Quality of Life in Gastric Cancer: Study

Researchers have found in a new study that cachexia index (CXI) may be a valuable indicator for assessing cancer cachexia and health-related quality of life in gastric cancer patients. The study was published in BMC Cancer journal by Yan H. and colleagues.

Cachexia, a multifaceted metabolic syndrome involving intense muscle wasting and weight loss, is well recognized to be connected with unfavorable clinical outcomes in GC patients. In the present study, CXI was calculated according to the following formula: skeletal muscle index (SMI) × serum albumin / neutrophil–lymphocyte ratio (NLR). The present study was conducted to determine if CXI could efficiently detect cachexia and foretell HRQoL impairments.

The analysis involved 431 patients with GC, made up of 309 men (71.7%) and 122 women (28.3%), with an age at median of 68 years. Diagnosis of cachexia was made according to both AWGC criteria and Fearon’s criteria. Univariate logistic regression and multivariate logistic regression analyses were employed to determine independent risk factors for cachexia and for poor HRQoL. ROC curve analysis was conducted to establish diagnostic performance of CXI in diagnosing cachexia, as well as calculate the area under the curve (AUC).

Results

• CXI scores were much lower in cachexia patients than in non-cachexia patients, according to both AWGC and Fearon’s definitions (p < 0.001).

• CXI was independently related to AWGC-defined cachexia after controlling for confounding variables (OR = 0.98, 95% CI: 0.97–0.99, p < 0.001) but was not related to Fearon-defined cachexia (OR = 1.00, 95% CI: 0.99–1.01, p = 0.601).

• ROC analysis identified an AUC of 0.752 for men and 0.717 for women in detection of AWGC-defined cachexia, with best cut-off scores of 74.46 and 43.80 respectively.

• Patients with low scores on CXI had more severe impairment on several HRQoL domains, and low CXI was independently linked with compromised HRQoL (OR = 1.79, 95% CI: 1.05–3.07, p = 0.033).

The research concluded that cachexia index is a useful and trustworthy biomarker for the diagnosis of cachexia according to AWGC criteria and for the prediction of poor HRQoL in gastric cancer patients. The integration of CXI into clinical practice would potentially improve patient surveillance and inform early interventions directed at enhancing survival as well as quality of life.

Reference:

Huang, Y., Huang, Z., Hou, W. et al. Cachexia index as a biomarker for cancer cachexia and quality of life in patients with gastric cancer. BMC Cancer 25, 1293 (2025). https://doi.org/10.1186/s12885-025-14752-2

Powered by WPeMatico

CDSCO Panel Defers Biosphere’s Colloidal Nano Silver Gel Trial, Seeks Full Data

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organisation (CDSCO) has deferred further action on Biosphere Clinical Research Pvt. Ltd.’s Colloidal Nano Silver Gel (SilverSole), after observing that the pharmacokinetic study details were not fully reflected in the presentation.

Additionally, the Committee directed Biosphere to submit the complete clinical trial protocol, detailed report, and toxicity data for review before any further decision could be taken.

The company had appeared before the committee to present findings from a Phase I clinical trial (Protocol No. BCR-VIR-003, dated May 12, 2025) that sought to evaluate the safety and pharmacokinetics of Colloidal Nano Silver Gel in healthy adult female subjects. The application was linked to an earlier recommendation dated July 25, 2024.

However, after deliberation, the SEC observed that the pharmacokinetic study details were not adequately reflected in the PowerPoint presentation submitted by the firm. The panel observed:

“Complete details with respect to the pharmacokinetics study are not reflected in PowerPoint presentation presented by firm.”

The committee also emphasized that Colloidal Nano Silver vaginal gel is not yet approved in India or in any other country. In view of this, it decided that a comprehensive review of the full study protocol, detailed report, and toxicity data would be required before taking any further decision on the clinical trial.

“Colloidal Nano Silver vaginal gel is not yet approved in India and other countries and opined that committee needs to review complete protocol, report and toxicity data for further necessary action,” the Expert Committee said.

Colloidal silver products have historically been promoted for their antimicrobial properties. However, global regulatory authorities, including the U.S. Food and Drug Administration (FDA), have repeatedly raised safety concerns due to lack of robust clinical evidence. The FDA had issued warning letters to companies marketing colloidal silver products with unapproved health claims, underscoring that such products require rigorous clinical validation before being considered safe for medical use

Also Read: Effective and Safe: Polycarbophil Vaginal Gel Extends Relief for Vaginal Atrophy in Menopausal Women, study reveals

Powered by WPeMatico